Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia

Breastfeeding Medicine

Volumn 6, Issue 2, 2011, Pages 85-88

  Teoh, Stephanie ^a   Ilett, Kenneth F ^b,c   Hackett, L Peter ^c   Kohan, Rolland ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Path West Laboratory Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIPRIDE; AMISULPRIDE; UNCLASSIFIED DRUG;

ADULT; ADVERSE DRUG REACTION; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; BREAST FEEDING; CASE REPORT; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG MILK LEVEL; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LACTATION; MILK; PEDIATRICIAN; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; TERM BIRTH;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BREAST FEEDING; CHILD DEVELOPMENT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIRECTIVE COUNSELING; DRUG MONITORING; FEMALE; HUMANS; INFANT; LACTATION; MATERNAL EXPOSURE; MILK, HUMAN; RISK FACTORS; SCHIZOPHRENIA; SULPIRIDE; WEANING;

EID: 79954513674     PISSN: 15568253     EISSN: None     Source Type: Journal    
DOI: 10.1089/bfm.2010.0016     Document Type: Article

References (18)

1. Amipride Product Information. Sigma Pharmaceuticals (Australia) Pty Ltd. 2010. www.pbs.gov.au/html/healthpro/search/results?term= Amipride%20400&publication=GE (accessed March 12, 2010).
2. Muller MJ, Regenbogen B, Sachse J, et al. Gender aspects in the clinical treatment of schizophrenic inpatients with ami-sulpride: A therapeutic drug monitoring study. Pharma-copsychiatry 2006;39:41-46.
3. Frankenburg WK, Dodds J, Archer P, et al. The Denver II: A major revision and restandardization of the Denver Devel-opmental Screening Test. Pediatrics 1992;89:91-97.
4. Ilett KF, Hackett LP. Study design and data analysis for assessing drug transfer into milk. In: Hale TW, Hartmann PE, eds. Hale & Hartmann's Textbook ofHuman Lactation. Hale Publishing, Amarillo, TX, 2007, pp. 611-626.
5. Lucas A, Gibbs JA, Lyster RL, et al. Creamatocrit: Simple clinical technique for estimating fat concentration and en-ergy value of human milk. BMJ 1978;1:1018-1020. (Pubitemid 8308864)
6. nd ed. Elsevier, Am-sterdam, 1996, pp. 67-74.
7. Thomann P. Non-compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, eds. TopFit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis Systemfor the PC. Gustav Fischer, Stuttgart, 1993, pp. 5-66.
8. nd ed. Elsevier, Amsterdam, 1996, pp. 47-58.
9. Chemical Abstract Services. SciFinder Scholar. American Chemical Society. 2010. cas.org./SCIFINDER/SCHOLAR/(accessed March 24, 2010).
10. Begg EJ, Atkinson HC, Duffull SB. Prospective evaluation of a model for the prediction of milk:plasma drug concentra-tions from physicochemical characteristics. Br J Clin Pharmacol 1992;33:501-505.
11. Kearns GL, McConnell RF Jr, Trang JM, et al. Appearance of ranitidine in breast milk following multiple dosing. Clin Pharm 1985;4:322-324. (Pubitemid 15025317)
12. McNamara PJ, Meece JA, Paxton E. Active transport of ci-metidine and ranitidine into the milk of Sprague Dawley rats. J Pharmacol Exp Ther 1996;277:1615-1621. (Pubitemid 27167179)
13. Gerk PM, Kuhn RJ, Desai NS, et al. Active transport of ni-trofurantoin into human milk. Pharmacotherapy 2001;21: 669-675. (Pubitemid 32506482)
14. Oo CY, Paxton EW, McNamara PJ. Active transport of ni-trofurantoin into rat milk. Adv Exp Med Biol 2001;501: 547-552. (Pubitemid 34102240)
15. Oo CY, Kuhn RJ, Desai N, et al. Active transport of ci-metidine into human milk. Clin Pharmacol Ther 1995;58: 548-555.
16. Alcorn J, Lu X, Moscow JA, et al. Transporter gene expres-sion in lactating and nonlactating human mammary epi-thelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 2002;303:487-496. (Pubitemid 35231217)
17. El Ela AA, Hartter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoac-tive compounds\implications for pharmacokinetics of se-lected substrates. J Pharm Pharmacol 2004;56:967-975. (Pubitemid 39140051)
18. Schmitt U, Abou El-Ela A, Guo LJ, et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhi-bition of P-glycoprotein (P-gp). J Neural Transm 2006;113: 787-801. (Pubitemid 43962774)